MetaVia Inc. — Earnings Release 2016

Nov 2, 2016

8-K 1 a16-20876_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d)*

*of the Securities Exchange Act of 1934*

Date of Report (Date of earliest event reported): November 2, 2016

*GEMPHIRE THERAPEUTICS INC.*

(Exact name of registrant as specified in its charter)

Delaware	001-37809	47-2389984
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

*17199 N. Laurel Park Drive, Suite 401*

*Livonia, Michigan 48152*

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (248) 681-9815

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\105733\16-20876-1\task8153060\20876-1-ba.htm',USER='105733',CD='Nov 1 21:20 2016'

*Item 2.02 Results of Operations and Financial Condition.*

On November 2, 2016, Gemphire Therapeutics Inc. (the *“Company”*** ) issued a press release reporting its financial results for the third quarter ended September 30, 2016. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

*Item 9.01 Financial Statements and Exhibits.*

*(d) Exhibits.*

Exhibit	Description
99.1	Press Release dated November 2, 2016 reporting financial results for the third quarter ended September 30, 2016.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105733\16-20876-1\task8153060\20876-1-ba.htm',USER='105733',CD='Nov 1 21:20 2016'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 2, 2016
By:	/s/ Jeffrey S. Mathiesen
	Jeffrey S. Mathiesen
	Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105733\16-20876-1\task8153060\20876-1-ba.htm',USER='105733',CD='Nov 1 21:20 2016'

*EXHIBIT INDEX*

Exhibit	Description
99.1	Press Release dated November 2, 2016 reporting financial results for the third quarter ended September 30, 2016.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105733\16-20876-1\task8153060\20876-1-ba.htm',USER='105733',CD='Nov 1 21:20 2016'